Xinhua Pharma Secures Drug Approval Boost
Company Announcements

Xinhua Pharma Secures Drug Approval Boost

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical Company Limited has announced the successful approval of their esomeprazole magnesium drug by the National Medical Products Administration. The company’s product, designed for treating acid-related stomach issues, has been cleared for marketing and sale. This approval could potentially influence the company’s stock as it expands its product reach both domestically and internationally.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua’s Generic Drug Receives Key Approval
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharmaceutical Gains Approval for Pentazocine
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharmaceutical Gains Key Drug Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App